| Jan HJ |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=3.398 ------>paper_class3=2 ------>paper_class2=1 ------>vol=In pre ------>confirm_bywho=leehorng ------>insert_bywho=leehorng ------>Jurnal_Rank=37.1 ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=1 ------>medlineContent= ------>unit=E0310 ------>insert_date=20081128 ------>iam=7 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Cancer lett ------>paper_name=Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. ------>confirm_date=20081128 ------>tch_id=081004 ------>pmid=19168281 ------>page1=1 ------>fullAbstract=We sought to investigate the molecular mechanisms by which rosiglitazone (RGZ) inhibits cell invasion in human glioma cells. In this study, we found that RGZ attenuated MMP-2 protein levels, MMP-2 gelatinolytic activity, and cell invasiveness through a PPAR-gamma independent pathway. RGZ increased mitogen activated protein kinase phosphatase-1 (MKP-1) expression. The addition of triptolide (a diterpenoid triepoxide, which blocked MKP-1 induction) abolished the inhibitory effects by RGZ. Furthermore, we demonstrated that the knock down of MKP-1 by MKP-1 specific small interference RNA reversed the reduction of MMP-2 secretion, and of cell invasiveness by RGZ. In contrast, the stable expression of MKP-1 in glioma cell lines decreased MMP-2 activity and cell invasiveness. These results suggest that RGZ may mediate the inhibitory effects through MKP-1 induction. Thus, MKP-1 could be a potential target in glioma therapy. ------>tmu_sno=None ------>sno=20016 ------>authors2=Lee CC ------>authors3=Lin YM ------>authors4=Lai JH ------>authors5=Wei HW ------>authors6=Lee HM ------>authors6_c= ------>authors=Jan HJ ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2008 ------>submit_flag=None ------>publish_month=1 |